Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Wyeth’s Pristiq Deemed “Approvable” By FDA

This article was originally published in The Pink Sheet Daily

Executive Summary

Approval of Effexor XR follow-on is contingent upon inspection of firm's Puerto Rico manufacturing plant.

Related Content

FDA Clears Wyeth’s Pristiq For Depression
Pristiq Low Dose Shows Benefit In Treating MDD
FDA Asks Wyeth For Additional Safety Study To Support Pristiq Vasomotor Claim
Wyeth Suggests Pristiq Could Surpass Effexor XR In Depression Market
Wyeth’s Pristiq Shows Reduction In Hot Flashes In Menopausal Women
FDA Clears Guayama Manufacturing Facility
FDA Completes Wyeth Guayama Inspection But Has Remaining Concerns
Wyeth Guayama Inspection Will Take Longer Than Anticipated
Wyeth’s Pristiq Best-Case Launch Scenario Targets Menopause Market
Wyeth Anticipates “Approvable” Letter For Effexor XR Follow-On





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts